Dr. Albiges on Next Steps for Immunotherapy in RCC

Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses the next steps for immunotherapy for patients with renal cell carcinoma (RCC).

There is now access to nivolumab (Opdivo) in most countries due to its efficacy in overall survival compared with everolimus (Afinitor) and its safety profile, explains Albiges.

However, given the risks that still exist, more needs to be done to continue to develop the treatment landscape, states Albiges. Physicians are now investigating combination strategies that might improve outcomes.